E-mail

E-mail a Wiley Online Library Link

Jerome C. Landry, Yang Feng, Steven J. Cohen, Charles A. Staley III, Richard Whittington, Elin Ruth Sigurdson, Halla Nimeiri, Udit Verma, Roshan S. Prabhu and Al Bowen Benson Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204 Cancer 119

Version of Record online: 3 JAN 2013 | DOI: 10.1002/cncr.27890

The addition of oxaliplatin and bevacizumab to fluoropyrimidine-based neoadjuvant chemoradiation for locally advanced rectal cancer resulted in pathologic tumor downstaging in the majority of patients, with a pathologic complete response rate of 17%. Increased wound healing delays and complications may have been related to the addition of bevacizumab, oxaliplatin, or both.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH